These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 37558531)

  • 21. How do we manage t(11;14) plasma cell disorders with venetoclax?
    Chakraborty R; Bhutani D; Lentzsch S
    Br J Haematol; 2022 Oct; 199(1):31-39. PubMed ID: 35594184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).
    Bahlis NJ; Baz R; Harrison SJ; Quach H; Ho SJ; Vangsted AJ; Plesner T; Moreau P; Gibbs SD; Coppola S; Yang X; Al Masud A; Ross JA; Bueno O; Kaufman JL
    J Clin Oncol; 2021 Nov; 39(32):3602-3612. PubMed ID: 34388020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma.
    Kaufman JL; Gasparetto C; Schjesvold FH; Moreau P; Touzeau C; Facon T; Boise LH; Jiang Y; Yang X; Dunbar F; Vishwamitra D; Unger S; Macartney T; Pesko J; Yu Y; Salem AH; Ross JA; Hong WJ; Maciag PC; Pauff JM; Kumar S
    Am J Hematol; 2021 Apr; 96(4):418-427. PubMed ID: 33368455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continued Success of Venetoclax in t(11;14) Multiple Myeloma Despite Negative Trials.
    Avigan ZM; Joshua Richter Md
    Oncology (Williston Park); 2024 Jun; 38(6):239-241. PubMed ID: 38899981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma.
    Matulis SM; Gupta VA; Neri P; Bahlis NJ; Maciag P; Leverson JD; Heffner LT; Lonial S; Nooka AK; Kaufman JL; Boise LH
    Leukemia; 2019 May; 33(5):1291-1296. PubMed ID: 30679802
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma With Venetoclax: A Single-Center Evaluation of Off-Label Use.
    Hughes ME; Landsburg DJ; Rubin DJ; Schuster SJ; Svoboda J; Gerson JN; Namoglu E; Nasta SD
    Clin Lymphoma Myeloma Leuk; 2019 Dec; 19(12):791-798. PubMed ID: 31648953
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natural history of multiple myeloma patients refractory to venetoclax: A single center experience.
    Maples KT; Nooka AK; Gupta V; Joseph NS; Heffner LT; Hofmeister C; Dhodapkar M; Matulis SM; Lonial S; Boise LH; Kaufman JL
    Am J Hematol; 2021 Mar; 96(3):E68-E71. PubMed ID: 33275813
    [No Abstract]   [Full Text] [Related]  

  • 28. Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.
    Pullarkat VA; Lacayo NJ; Jabbour E; Rubnitz JE; Bajel A; Laetsch TW; Leonard J; Colace SI; Khaw SL; Fleming SA; Mattison RJ; Norris R; Opferman JT; Roberts KG; Zhao Y; Qu C; Badawi M; Schmidt M; Tong B; Pesko JC; Sun Y; Ross JA; Vishwamitra D; Rosenwinkel L; Kim SY; Jacobson A; Mullighan CG; Alexander TB; Stock W
    Cancer Discov; 2021 Jun; 11(6):1440-1453. PubMed ID: 33593877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.
    Wang M; Ramchandren R; Chen R; Karlin L; Chong G; Jurczak W; Wu KL; Bishton M; Collins GP; Eliadis P; Peyrade F; Lee Y; Eckert K; Neuenburg JK; Tam CS
    J Hematol Oncol; 2021 Oct; 14(1):179. PubMed ID: 34717692
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Venetoclax-based salvage in multiple myeloma with (11;14) translocation after suboptimal response to first-line therapy].
    Szita VR; Wiedemann Á; Syoreni S; Tóth A; Ruff E; Gaál L; Masszi T; Varga G
    Orv Hetil; 2023 Jun; 164(23):894-899. PubMed ID: 37302128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma.
    Wong KY; Chim CS
    J Pharm Pharmacol; 2020 May; 72(5):728-737. PubMed ID: 32066201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma Patients.
    Freise KJ; Jones AK; Verdugo ME; Menon RM; Maciag PC; Salem AH
    Clin Pharmacol Ther; 2017 Dec; 102(6):970-976. PubMed ID: 28419431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experience of using venetoclax in relapsed T- cell lymphoma.
    Zain J; Lunning M; Rosen S
    Leuk Lymphoma; 2024 Oct; 65(10):1538-1539. PubMed ID: 38885346
    [No Abstract]   [Full Text] [Related]  

  • 34. Secondary plasma cell leukaemia treated with single agent venetoclax.
    Glavey SV; Flanagan L; Bleach R; Kelly C; Quinn J; Ní Chonghaile T; Murphy P
    Br J Haematol; 2020 Aug; 190(4):e242-e245. PubMed ID: 32525557
    [No Abstract]   [Full Text] [Related]  

  • 35. Dexamethasone treatment promotes Bcl-2 dependence in multiple myeloma resulting in sensitivity to venetoclax.
    Matulis SM; Gupta VA; Nooka AK; Hollen HV; Kaufman JL; Lonial S; Boise LH
    Leukemia; 2016 May; 30(5):1086-93. PubMed ID: 26707935
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial.
    Kumar SK; Harrison SJ; Cavo M; de la Rubia J; Popat R; Gasparetto C; Hungria V; Salwender H; Suzuki K; Kim I; Punnoose EA; Hong WJ; Freise KJ; Yang X; Sood A; Jalaluddin M; Ross JA; Ward JE; Maciag PC; Moreau P
    Lancet Oncol; 2020 Dec; 21(12):1630-1642. PubMed ID: 33129376
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Venetoclax salvage therapy in relapsed/refractory multiple myeloma.
    Steinhardt MJ; Truger M; Bittrich M; Zhou X; Noderer J; Riedhammer C; Xiao X; Gawlas S; Weis P; Eisele F; Haferlach C; Mersi J; Waldschmidt J; Einsele H; Rasche L; Kortüm KM
    Haematologica; 2024 Mar; 109(3):979-981. PubMed ID: 37794827
    [No Abstract]   [Full Text] [Related]  

  • 38. Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma.
    Zhou Z; Zhang L; Wang X; Li X; Li L; Fu X; Zhang X; Li Z; Sun Z; Zhang M
    Ann Hematol; 2021 Jun; 100(6):1509-1516. PubMed ID: 33900450
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia.
    Vitale C; Ferrajoli A
    Expert Rev Hematol; 2020 Aug; 13(8):885-894. PubMed ID: 32700593
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of anti-bacterial prophylaxis on the outcome of patients treated with venetoclax-based regimens for relapsed/refractory plasma cell dyscrasias: Real-life data.
    Avivi I; Gatt ME; Luttwak E; Magen H; Dally N; Cohen YC; Benyamini N; Lavi N
    Leuk Res; 2020 Oct; 97():106429. PubMed ID: 32861018
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.